Is Aducanumab for LMICs? Promises and Challenges

Aducanumab, a human monoclonal antibody, was approved in June of 2021 as the first disease-modifying treatment for Alzheimer’s disease by the United States Food and Drug Administration (U.S. FDA). A substantial proportion of patients with Alzheimer’s disease live in low- and middle-income countries...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunawardena, Illangage P. C., Retinasamy, Thaarvena, Shaikh, Mohd. Farooq
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615623/
https://www.ncbi.nlm.nih.gov/pubmed/34827546
http://dx.doi.org/10.3390/brainsci11111547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615623/
https://www.ncbi.nlm.nih.gov/pubmed/34827546
http://dx.doi.org/10.3390/brainsci11111547

Ejemplares similares